Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
13.97
-1.15 (-7.61%)
At close: Nov 15, 2024, 4:00 PM
14.35
+0.38 (2.72%)
After-hours: Nov 15, 2024, 7:12 PM EST
Intellia Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for NTLA stock have an average target of 57.25, with a low estimate of 18 and a high estimate of 120. The average target predicts an increase of 309.81% from the current stock price of 13.97.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NTLA stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 4 | 5 | 5 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 4 | 4 | 4 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 13 | 15 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $70 → $60 | Buy | Maintains | $70 → $60 | +329.49% | Nov 11, 2024 |
| Barclays | Barclays | Buy Maintains $76 → $55 | Buy | Maintains | $76 → $55 | +293.70% | Nov 8, 2024 |
| Citigroup | Citigroup | Hold Maintains $25 → $19 | Hold | Maintains | $25 → $19 | +36.01% | Oct 25, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $31 → $20 | Hold | Maintains | $31 → $20 | +43.16% | Oct 25, 2024 |
| Baird | Baird | Hold Maintains $24 → $18 | Hold | Maintains | $24 → $18 | +28.85% | Oct 25, 2024 |
Financial Forecast
Revenue This Year
54.68M
from 36.28M
Increased by 50.73%
Revenue Next Year
59.43M
from 54.68M
Increased by 8.69%
EPS This Year
-5.53
from -5.42
EPS Next Year
-5.69
from -5.53
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 83.8M | 220.5M | 374.8M | ||
| Avg | 54.7M | 59.4M | 91.6M | ||
| Low | 35.2M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 131.0% | 303.3% | 530.7% | ||
| Avg | 50.7% | 8.7% | 54.1% | ||
| Low | -3.0% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -5.05 | -4.22 | -3.52 | ||
| Avg | -5.53 | -5.69 | -5.78 | ||
| Low | -6.29 | -7.21 | -8.26 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.